{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:32:56Z","timestamp":1793277176266,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013423.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000}}],"reference-count":184,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013423.pub3","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:18:37Z","timestamp":1791519517000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmaceutical industry information and promotional strategies aimed at prescribers"],"prefix":"10.1002","volume":"2026","author":[{"given":"Barbara","family":"Mintzes","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health; The University of Sydney; Camperdown, Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5120-8029","authenticated-orcid":false,"given":"Joel","family":"Lexchin","sequence":"additional","affiliation":[{"name":"School of Health Policy and Management; York University; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7640-8614","authenticated-orcid":false,"given":"Quinn","family":"Grundy","sequence":"additional","affiliation":[{"name":"Lawrence Bloomberg Faculty of Nursing; University of Toronto; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-0440","authenticated-orcid":false,"given":"Alice","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Department for Health; University of Bath; Bath UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3525-4663","authenticated-orcid":false,"given":"Geoffrey KP","family":"Spurling","sequence":"additional","affiliation":[{"name":"General Practice Clinical Unit, School of Medicine; The University of Queensland; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6670-4874","authenticated-orcid":false,"given":"Riaz","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Anschutz Medical Campus; Denver CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1893-6651","authenticated-orcid":false,"given":"Lisa","family":"Bero","sequence":"additional","affiliation":[{"name":"Center for Bioethics and Humanities; The University of Colorado Anschutz Medical Campus; Aurora, Colorado NSW USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"16","key":"10.1002\/14651858.CD013423.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archinternmed.2011.256","article-title":"Principles of conservative prescribing","volume":"171","author":"Schiff","year":"2011","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013423.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/j.1365-2125.2012.04413.x","article-title":"Balanced prescribing: principles and challenges","volume":"74","author":"Aronson","year":"2012","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"105027","DOI":"10.1016\/j.healthpol.2024.105027","article-title":"Factors influencing the effects of policies and interventions to promote the appropriate use of medicines in high-income countries: a rapid realist review","volume":"142","author":"Charbonneau","year":"2024","journal-title":"Health Policy"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0004|cit4","unstructured":"Alves LT Lexchin J Mintzes B Medicines information and the regulation of the promotion of pharmaceuticals Science and Engineering Ethics 10.1007\/s11948-018-0041-5"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"J1855","DOI":"10.1136\/bmj.j1855","article-title":"US drug marketing: how does promotion correspond with health value?","volume":"357","author":"Greenway","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"E724","DOI":"10.9778\/cmajo.20170089","article-title":"The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis","volume":"5","author":"Lexchin","year":"2017","journal-title":"Canadian Medical Association Journal Open"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0007|cit7","volume-title":"Ethical Criteria for Medicinal Drug Promotion","author":"World Health Organization","year":"1988"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Parker L Williams J Bero L Ethical drug marketing criteria for the 21st century BMJ 2018 361 k1809 10.1136\/bmj.k1809","DOI":"10.1136\/bmj.k1809"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/fampra\/20.1.61","article-title":"Influences on GPs' decision to prescribe new drugs: the importance of who says what","volume":"20","author":"Prosser","year":"2003","journal-title":"Family Practice"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0010|cit10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002215","article-title":"Capitation, salary, fee-for-service and mixed systems of payment: effects on the behaviour of primary care physicians","author":"Gosden","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"e0155035","DOI":"10.1371\/journal.pone.015503","article-title":"Prescription drug promotion from 2001-2014: data from the U.S. Food and Drug Administration","volume":"11","author":"Sullivan","year":"2016","journal-title":"PLOS One"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1371\/journal.pmed.0050001","article-title":"The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States","volume":"5","author":"Gagnon","year":"2008","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0013|cit13","unstructured":"Persuading the prescribers: pharmaceutical industry marketing and its influence on physicians and patients www.pewtrusts.org\/en\/research-and-analysis\/fact-sheets\/2013\/11\/11\/persuading-the-prescribers-pharmaceutical-industry-marketing-and-its-influence-on-physicians-and-patients"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jama.2018.19320","article-title":"Medical marketing in the United States, 1997-2016","volume":"321","author":"Schwartz","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"e241581","DOI":"10.1001\/jamahealthforum.2024.1581","article-title":"Quantifying industry spending on promotional events using open payments data","volume":"5","author":"Grundy","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"10383","key":"10.1002\/14651858.CD013423.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/s0140-6736(23)00013-2","article-title":"Defining and conceptualising the commercial determinants of health","volume":"401","author":"Gilmore","year":"2023","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0017|cit17","volume-title":"Lethal but Legal: Corporations, Consumption, and Protecting Public Health","author":"Freudenberg","year":"2014"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/1468-0009.12339","article-title":"Systems thinking as a framework for analyzing commercial determinants of health","volume":"96","author":"Knai","year":"2018","journal-title":"Milbank Quarterly"},{"issue":"12","key":"10.1002\/14651858.CD013423.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1016\/S2214-109X(16)30217-0","article-title":"The commercial determinants of health","volume":"4","author":"Kickbusch","year":"2016","journal-title":"Lancet Global Health"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"e1000333","DOI":"10.1371\/journal.pmed.1000333","article-title":"Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world","volume":"7","author":"Ni\u00ebns","year":"2010","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0140-6736(08)61779-1","article-title":"Trade, TRIPS, and pharmaceuticals","volume":"373","author":"Smith","year":"2009","journal-title":"Lancet"},{"issue":"10383","key":"10.1002\/14651858.CD013423.pub3-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/s0140-6736(23)00011-9","article-title":"Commercial determinants of health: future directions","volume":"401","author":"Friel","year":"2023","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1136\/bmj.324.7342.886","article-title":"Selling sickness: the pharmaceutical industry and disease mongering","volume":"324","author":"Moynihan","year":"2002","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"e1001500","DOI":"10.1371\/journal.pmed.1001500","article-title":"Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States","volume":"10","author":"Moynihan","year":"2013","journal-title":"PLOS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013423.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.7326\/0003-4819-145-4-200608150-00008","article-title":"Narrative review: the promotion of gabapentin: an analysis of internal industry documents","volume":"145","author":"Steinman","year":"2006","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013423.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"e1000352","DOI":"10.1371\/journal.pmed.1000352","article-title":"Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review","volume":"7","author":"Spurling","year":"2010","journal-title":"PLOS Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013423.pub3-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1007\/s11606-013-2411-7","article-title":"Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States","volume":"28","author":"Mintzes","year":"2013","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/scientificamericanmind0104-70","article-title":"The science of persuasion","volume":"284","author":"Cialdini","year":"2001","journal-title":"Scientific American"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1525\/maq.2004.18.3.325","article-title":"Thick prescriptions: toward an interpretation of pharmaceutical sales practices","volume":"18","author":"Oldani","year":"2004","journal-title":"Medical Anthropology Quarterly"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.healthpol.2018.01.010","article-title":"Reconciling a \u201cpleasant exchange\u201d with evidence of information bias: a three-country study on pharmaceutical sales visits in primary care","volume":"122","author":"Reynolds","year":"2018","journal-title":"Health Policy"},{"issue":"9","key":"10.1002\/14651858.CD013423.pub3-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1097\/SMJ.0b013e3181814d52","article-title":"The impact of drug samples on prescribing to the uninsured","volume":"101","author":"Miller","year":"2008","journal-title":"Southern Medical Journal"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1529-2126(08)12014-8","article-title":"How advertising for psychotropics constructs an enhanced gendered self","volume":"12","author":"Riska","year":"2008","journal-title":"Advances in Gender Research"},{"issue":"9","key":"10.1002\/14651858.CD013423.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"e016408","DOI":"10.1136\/bmjopen-2017-016408","article-title":"Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review","volume":"7","author":"Fickweiler","year":"2017","journal-title":"BMJ Open"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"e0286339","DOI":"10.1371\/journal.pone.0286339","article-title":"Changes in Japanese physicians' relationships with the pharmaceutical industry between 2008 and 2021: a national survey","volume":"18","author":"Saito","year":"2023","journal-title":"PLOS One"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1509\/jmkg.65.3.79.18329","article-title":"Promotion of prescription drugs and its impact on physicians' choice behavior","volume":"65","author":"Gonul","year":"2001","journal-title":"Journal of Marketing"},{"issue":"9","key":"10.1002\/14651858.CD013423.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jama.1994.03510330062035","article-title":"Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary","volume":"271","author":"Chren","year":"1994","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/bf02600542","article-title":"Pharmaceutical representatives in academic medical centers","volume":"5","author":"Lurie","year":"1990","journal-title":"Journal of General Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013423.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"e0175493","DOI":"10.1371\/journal.pone.0175493","article-title":"Association between physicians' interaction with pharmaceutical companies and their clinical practices: a systematic review and meta-analysis","volume":"12","author":"Brax","year":"2017","journal-title":"PLOS One"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.7326\/m20-5665","article-title":"Are financial payments from the pharmaceutical industry associated with physician prescribing? : a systematic review","volume":"174","author":"Mitchell","year":"2021","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","article-title":"Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries","volume":"176","author":"DeJong","year":"2016","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0041|cit41","unstructured":"World Bank country and lending groups, country classification data Available from: datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0042|cit42","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.5688\/aj720243","article-title":"Response rates and responsiveness for surveys, standards, and the Journal","volume":"72","author":"Fincham","year":"2008","journal-title":"American Journal of Pharmaceutical Education"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","article-title":"Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries","volume":"176","author":"DeJong","year":"2016","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"l6015","DOI":"10.1136\/bmj.l6015","article-title":"Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: retrospective study using the French Transparency in Healthcare and National Health Data System databases","volume":"367","author":"Goupil","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0047|cit47","unstructured":"Covidence Veritas Health Innovation 2026"},{"issue":"7","key":"10.1002\/14651858.CD013423.pub3-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0049|cit49","unstructured":"Data collection form. EPOC resources for review authors, 2017 epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"Journal of Biomedical Informatics"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0051|cit51","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2026"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0052|cit52","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0053|cit53","unstructured":"Suggested risk of bias criteria for EPOC reviews. EPOC resources for review authors, 2017 epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0055|cit55","unstructured":"Eldridge SM Campbell MK Campbell MJ Drahota A Giraudeau B Reeves BC Revised Cochrane risk of bias tool for randomized trials (RoB 2): additional considerations for cluster-randomized trials (RoB 2 CRT). Version 18 March 2021 Available from https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool\/rob-2-for-cluster-randomized-trials"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0056|cit56","unstructured":"Higgins JP Li T on behalf of the RoB 2 Working Group on crossover trials Revised Cochrane risk of bias tool for randomized trials (RoB 2). Additional considerations for crossover trials. Version 22 August 2019 Available from: https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool\/rob-2-for-crossover-trials"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","article-title":"The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence","volume":"3","author":"Munn","year":"2014","journal-title":"International Journal of Health Policy and Management"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Sterne JA Hern\u00e1n MA McAleenan A Reeves BC Higgins JP Chapter 25: Assessing risk of bias in a non-randomized study (last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook 10.1002\/9781119536604.ch25","DOI":"10.1002\/9781119536604.ch25"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0059|cit59","unstructured":"Higgins JP Churchill R Chandler J Cumpston MS Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.2.0"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Medical Research Methodology"},{"issue":"4","key":"10.1002\/14651858.CD013423.pub3-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1017\/S0266462303000576","article-title":"Interrupted time series design in health technology assessment","volume":"19","author":"Ramsay","year":"2003","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0062|cit62","unstructured":"Analysis in EPOC reviews. EPOC Resources for review authors 2017 epoc.cochrane.org\/resources\/epoc-resources-review-authors"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0063|cit63","unstructured":"Rohatgi A WebPlotDigitizer: Extract data from charts Available from https:\/\/automeris.io\/"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0064|cit64","unstructured":"Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0066|cit66","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1472-6963-9-6","article-title":"Is new drug prescribing in primary care specialist induced?","volume":"9","author":"Florentinus","year":"2009","journal-title":"BMC Health Services Research"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"e0205524","DOI":"10.1371\/journal.pone.0205524","article-title":"Comparison of prescribing practices for older adults treated by female versus male physicians: a retrospective cohort study","volume":"13","author":"Rochon","year":"2018","journal-title":"PLOS One"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"e57132","DOI":"10.1371\/journal.pone.0057132","article-title":"Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers","volume":"8","author":"Akl","year":"2013","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jclinepi.2013.03.014","article-title":"Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers","volume":"66","author":"Ebrahim","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0072|cit72","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence [last updated August 2023]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from www.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"h870","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"Iorio","year":"2015","journal-title":"BMJ"},{"issue":"7650","key":"10.1002\/14651858.CD013423.pub3-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0075|cit75","unstructured":"EPOC worksheets for preparing a 'Summary of findings' table using GRADE. EPOC resources for review authors, 2017 epoc.cochrane.org\/epoc-specific-resources-review-authors"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jama.1994.03510330062035","article-title":"Physicians\u2019 behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary","volume":"271","author":"Chren","year":"1994","journal-title":"JAMA"},{"issue":"11","key":"10.1002\/14651858.CD013423.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1016\/j.socscimed.2006.07.019","article-title":"Determinants for the adoption of angiotensin II receptor blockers by general practitioners","volume":"63","author":"Greving","year":"2006","journal-title":"Social Science & Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0078|cit78","first-page":"30","article-title":"Correlates of physicians' prescribing behavior","volume":"9","author":"Becker","year":"1972","journal-title":"Inquiry"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-10-4","article-title":"Characteristics of primary health care units with focus on drug information from the pharmaceutical industry and adherence to prescribing objectives: a cross-sectional study","volume":"10","author":"Carlzon","year":"2010","journal-title":"BMC Clinical Pharmacology"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1472-6963-7-132","article-title":"Determinants of the range of drugs prescribed in general practice: a cross-sectional analysis","volume":"7","author":"De Bakker","year":"2007","journal-title":"BMC Health Services Research"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.socscimed.2009.12.016","article-title":"Is the \"practice style\" hypothesis relevant for general practitioners? An analysis of antibiotics prescription for acute rhinopharyngitis","volume":"70","author":"Mousques","year":"2010","journal-title":"Social Science & Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/fampra\/cmi074","article-title":"Differences in prescribing between GPs: impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives","volume":"22","author":"Muijrers","year":"2005","journal-title":"Family Practice"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0083|cit83","first-page":"118","article-title":"Differential education concerning therapeutics and resultant physician prescribing patterns","volume":"47","author":"Becker","year":"1972","journal-title":"Journal of Medical Education"},{"issue":"7","key":"10.1002\/14651858.CD013423.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1751-7176.2012.00651.x","article-title":"Can access limits on sales representatives to physicians affect clinical prescription decisions? A study of recent events with diabetes and lipid drugs","volume":"14","author":"Chressanthis","year":"2012","journal-title":"Journal of Clinical Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1257\/pol.20200044","article-title":"Drug diffusion through peer networks: the influence of industry payments","volume":"14","author":"Agha","year":"2022","journal-title":"American Economic Journal: Economic Policy"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/1475-6773.13064","article-title":"Physician characteristics, industry transfers, and pharmaceutical prescribing: empirical evidence from Medicare and the Physician Payment Sunshine Act","volume":"54","author":"Brunt","year":"2019","journal-title":"Health Services Research"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"104402","DOI":"10.1016\/j.jpubeco.2021.104402","article-title":"Drug firms' payments and physicians' prescribing behavior in Medicare Part D","volume":"197","author":"Carey","year":"2021","journal-title":"Journal of Public Economics"},{"issue":"7","key":"10.1002\/14651858.CD013423.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s11606-019-04897-9","article-title":"Association of pharmaceutical manufacturer payments to physicians and prescribing dosage of opioids","volume":"34","author":"Fleischman","year":"2019","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"e180482","DOI":"10.1001\/jamanetworkopen.2018.0482","article-title":"Industry payments to physician specialists who prescribe repository corticotropin","volume":"1","author":"Hartung","year":"2018","journal-title":"JAMA Network Open"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2016.08.001","article-title":"Association between industry payments and anti-vascular endothelial growth factor use in Medicare beneficiaries","volume":"1","author":"Mahr","year":"2017","journal-title":"Ophthalmology Retina"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12913-018-3043-8","article-title":"Association between industry payments and prescribing costly medications: an observational study using Open Payments and Medicare Part D data","volume":"18","author":"Sharma","year":"2018","journal-title":"BMC Health Services Research"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2016.09.026","article-title":"Open Payments database: anti-vascular endothelial growth factor agent payments to ophthalmologists","volume":"173","author":"Singh","year":"2017","journal-title":"American Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamaophthalmol.2016.1678","article-title":"Physician-industry interactions and anti-vascular endothelial growth factor use among US ophthalmologists","volume":"134","author":"Taylor","year":"2016","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"e075512","DOI":"10.1136\/bmj-2023-075512","article-title":"Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study","volume":"383","author":"Mitchell","year":"2023","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamainternmed.2022.7018","article-title":"Association between pharmaceutical industry marketing payments to physicians and intra-articular hyaluronic acid administration to medicare beneficiaries","volume":"183","author":"Uppal","year":"2023","journal-title":"JAMA Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1080\/08820538.2021.1922710","article-title":"A 5-year analysis of physician-industry interactions, physician gender, and anti-VEGF use in US ophthalmologists","volume":"36","author":"Watane","year":"2021","journal-title":"Seminars in Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive And Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"4","key":"10.1002\/14651858.CD013423.pub3-BIB0098|cit98","first-page":"285","article-title":"Restocking the sample closet: results of a trial to alter medication prescribing","volume":"15","author":"Mukamal","year":"2002","journal-title":"Journal of the American Board of Family Practice\/American Board of Family Practice"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"f264","DOI":"10.1136\/bmj.f264","article-title":"Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis","volume":"346","author":"King","year":"2013","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1377\/hlthaff.2013.0939","article-title":"Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children","volume":"33","author":"Larkin","year":"2014","journal-title":"Health Affairs"},{"issue":"4","key":"10.1002\/14651858.CD013423.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/hec.3323","article-title":"Effects of physician-directed pharmaceutical promotion on prescription behaviors: longitudinal evidence","volume":"26","author":"Datta","year":"2017","journal-title":"Health Economics"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.285.11.1443","article-title":"Industry-sponsored grand rounds and prescribing behavior","volume":"285","author":"Dieperink","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/07359683.2011.545341","article-title":"Asymmetric responsiveness of physician prescription behavior to drug promotion of competitive brands within an established therapeutic drug class","volume":"28","author":"Pedan","year":"2011","journal-title":"Health Marketing Quarterly"},{"issue":"2-3","key":"10.1002\/14651858.CD013423.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1023\/B:MARK.0000047389.93584.09","article-title":"Responsiveness of physician prescription behavior to salesforce effort: an individual level analysis","volume":"15","author":"Manchanda","year":"2004","journal-title":"Marketing Letters"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/fampra\/cmp010","article-title":"Impact of pharmaceutical representative visits on GPs' drug preferences","volume":"26","author":"Sondergaard","year":"2009","journal-title":"Family Practice"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3917\/spub.153.0353","article-title":"Factors associated with drug prescription in general practice: a multicenter cross-sectional study","volume":"27","author":"Darmon","year":"2015","journal-title":"Sante Publique (Vandoeuvre-Les-Nancey)"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1634\/theoncologist.2018-0423","article-title":"Evaluating the strength of the association between industry payments and prescribing practices in oncology","volume":"24","author":"Mitchell","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.urpr.2017.03.012","article-title":"Financial relationships between urologists and industry: an analysis of Open Payments data","volume":"5","author":"Maruf","year":"2018","journal-title":"Urology Practice"},{"issue":"9","key":"10.1002\/14651858.CD013423.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"e232951","DOI":"10.1001\/jamahealthforum.2023.2951","article-title":"Medicare Part B spending on macular degeneration treatments associated with manufacturer payments to ophthalmologists","volume":"4","author":"Dickson","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jamainternmed.2018.1999","article-title":"Association of pharmaceutical industry marketing of opioid products to physicians with subsequent opioid prescribing","volume":"178","author":"Hadland","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/jech-2020-214021","article-title":"Association between industry payments for opioid products and physicians' prescription of opioids: observational study with propensity-score matching","volume":"74","author":"Inoue","year":"2020","journal-title":"Journal of Epidemiology and Community Health"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1176\/appi.ps.202000251","article-title":"Association of pharmaceutical industry payments to physicians with prescription and Medicare expenditures for pimavanserin","volume":"72","author":"Mehta","year":"2020","journal-title":"Psychiatric Services (Washington DC)"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"e1003645","DOI":"10.1371\/journal.pmed.1003645","article-title":"Association between industry payments and prescriptions of long-acting insulin: an observational study with propensity score matching","volume":"18","author":"Inoue","year":"2021","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"113942","DOI":"10.1016\/j.socscimed.2021.113942","article-title":"Industry payments and physicians prescriptions: effect of a payment restriction policy","volume":"278","author":"Ansari","year":"2021","journal-title":"Social Science & Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"e200392","DOI":"10.1212\/CPJ.0000000000200392","article-title":"Dissemination of VMAT-2 inhibitors: a new class drug for tardive dyskinesia and Huntington disease","volume":"15","author":"Ma","year":"2025","journal-title":"Neurology Clinical Practice"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ygyno.2023.12.011","article-title":"Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States","volume":"181","author":"Murayama","year":"2024","journal-title":"Gynecologic Oncology"},{"issue":"22","key":"10.1002\/14651858.CD013423.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1002\/cncr.30914","article-title":"The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide","volume":"123","author":"Bandari","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.urpr.2016.03.007","article-title":"The relationship of industry payments to prescribing behavior: a study of degarelix and denosumab","volume":"4","author":"Bandari","year":"2017","journal-title":"Urology Practice"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"e1003151","DOI":"10.1371\/journal.pmed.1003151","article-title":"Impact of physicians' participation in non-interventional post-marketing studies on their prescription habits: a retrospective 2-armed cohort study in Germany","volume":"17","author":"Koch","year":"2020","journal-title":"PLOS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0120|cit120","first-page":"181","article-title":"Industry payments to physicians and prescribing branded memantine and donepezil combination","volume":"11","author":"Marcum","year":"2021","journal-title":"Neurology: Clinical Practice"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jsat.2019.06.014","article-title":"Provider-directed marketing may increase prescribing of medications for opioid use disorder","volume":"104","author":"Nguyen","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/add.14509","article-title":"Pharmaceutical payments to physicians may increase prescribing for opioids","volume":"114","author":"Nguyen","year":"2019","journal-title":"Addiction (Abingdon, England)"},{"issue":"12","key":"10.1002\/14651858.CD013423.pub3-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1002\/hec.4424","article-title":"Pharmaceutical opioid marketing and physician prescribing behavior","volume":"30","author":"Beilfuss","year":"2021","journal-title":"Health Economics"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"E007521","DOI":"10.1161\/CIRCOUTCOMES.120.007521","article-title":"Association between industry marketing payments and prescriptions for PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibitors in the United States","volume":"14","author":"Inoue","year":"2021","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"issue":"9","key":"10.1002\/14651858.CD013423.pub3-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1016\/j.jaip.2023.05.030","article-title":"Pharmaceutical industry-sponsored meals and prescriptions of biologics for asthma","volume":"11","author":"Murayama","year":"2023","journal-title":"Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"12","key":"10.1002\/14651858.CD013423.pub3-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1111\/liv.16111","article-title":"Pharmaceutical industry payments and prescriptions of direct acting antiviral drugs for hepatitis C virus infection","volume":"44","author":"Murayama","year":"2024","journal-title":"Liver International"},{"issue":"12","key":"10.1002\/14651858.CD013423.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"e234020","DOI":"10.1001\/jamahealthforum.2023.4020","article-title":"Industry payments for vibegron and prescribing patterns among urologic clinicians","volume":"4","author":"Polcari","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"10","key":"10.1002\/14651858.CD013423.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"e0186060","DOI":"10.1371\/journal.pone.0186060","article-title":"Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia","volume":"12","author":"Wood","year":"2017","journal-title":"PLOS One"},{"issue":"12","key":"10.1002\/14651858.CD013423.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"e0209383","DOI":"10.1371\/journal.pone.0209383","article-title":"Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing","volume":"13","author":"Zezza","year":"2018","journal-title":"PLOS One"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"e14962","DOI":"10.1111\/1756-185X.14962","article-title":"Industry-sponsored meal payments are associated with prescriptions and Medicare expenditures on brand-name colchicine in the United States","volume":"27","author":"Murayama","year":"2024","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/jep.13956","article-title":"Pharmaceutical industry-sponsored meals are associated with increased prescriptions and Medicare spending for dupilumab among dermatologists in the United States","volume":"30","author":"Murayama","year":"2024","journal-title":"Journal of Evaluation in Clinical Practice"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0132|cit132","first-page":"A6603","article-title":"Association between industry payments and prescription of inhaled medications: an observational analysis of Open Payments and Medicare Part D data","volume":"209","author":"Nadeem","year":"2024","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"102887","DOI":"10.1016\/j.jhealeco.2024.102887","article-title":"The cost of influence: how gifts to physicians shape prescriptions and drug costs","volume":"95","author":"Newham","year":"2024","journal-title":"Journal of Health Economics"},{"issue":"9","key":"10.1002\/14651858.CD013423.pub3-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jamaophthalmol.2022.2757","article-title":"Association between Open Payments-reported industry transfers of value and prostaglandin analog prescribing in the US","volume":"140","author":"Nguyen","year":"2022","journal-title":"JAMA Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10488-019-00974-7","article-title":"Receipt of promotional payments at the individual and physician network level associated with higher branded antipsychotic prescribing rates","volume":"47","author":"Hollands","year":"2020","journal-title":"Administration and Policy in Mental Health"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/0194599818774739","article-title":"The association of industry payments to physicians with prescription of brand-name intranasal corticosteroids","volume":"159","author":"Morse","year":"2018","journal-title":"Otolaryngology - Head & Neck Surgery"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/jamainternmed.2018.0776","article-title":"Pharmaceutical industry payments and oncologists' selection of targeted cancer therapies in medicare beneficiaries","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0138|cit138","first-page":"14","article-title":"Industry marketing payments to physicians and prescription patterns for sacubitril\/valsartan in the USA","volume":"14","author":"Murayama","year":"2025","journal-title":"Heart (British Cardiac Society)"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11606-018-4698-x","article-title":"Impact of industry payments on prescribing patterns for tumor necrosis factor inhibitors among Medicare beneficiaries","volume":"34","author":"Singh","year":"2019","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0140|cit140","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.mayocp.2021.08.026","article-title":"Association between payments by pharmaceutical manufacturers and prescribing behavior in rheumatology","volume":"97","author":"Duarte-Garc\u00eda","year":"2022","journal-title":"Mayo Clinic Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/0194599818803337","article-title":"Industry payments to physicians and prescriptions of brand-name proton-pump inhibitors","volume":"160","author":"Morse","year":"2019","journal-title":"Otolaryngology \u2013 Head & Neck Surgery"},{"issue":"23","key":"10.1002\/14651858.CD013423.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1001\/jama.295.23.2759","article-title":"How conducting a clinical trial affects physicians' guideline adherence and drug preferences","volume":"295","author":"Andersen","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"e200424","DOI":"10.1212\/CPJ.0000000000200424","article-title":"Industry payments and branded glatiramer acetate prescribing in the US Medicare Program","volume":"15","author":"Hartung","year":"2025","journal-title":"Neurology Clinical Practice"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s11606-019-05470-0","article-title":"Association between opioid prescribing in Medicare and pharmaceutical company gifts by physician specialty","volume":"35","author":"Hollander","year":"2020","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2021.10.042","article-title":"Promotional payments to medical oncologists and urologists and prescriptions for abiraterone and enzalutamide","volume":"161","author":"Lai","year":"2022","journal-title":"Urology"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2018.04.008","article-title":"The receipt of industry payments is associated with prescribing promoted alpha-blockers and overactive bladder medications","volume":"117","author":"Modi","year":"2018","journal-title":"Urology"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1097\/IAE.0000000000003081","article-title":"Trends in intravitreal corticosteroid agent use by US ophthalmologists in Medicare beneficiaries and association with physician-industry interactions","volume":"41","author":"Watane","year":"2021","journal-title":"Retina (Philadelphia, PA)"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1080\/09273948.2023.2272171","article-title":"Trends in immunosuppressive agent use for non-infectious uveitis by US ophthalmologists in Medicare beneficiaries and association with physician-industry interactions","volume":"32","author":"Watane","year":"2024","journal-title":"Ocular Immunology and Inflammation"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/UPJ.0000000000000017","article-title":"Receiving industry payments is associated with prescribing habits of tadalafil","volume":"6","author":"Chua","year":"2019","journal-title":"Urology Practice"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.amjmed.2005.02.031","article-title":"Do drug samples influence resident prescribing behavior? A randomized trial","volume":"118","author":"Adair","year":"2005","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3122\/jabfm.19.5.443","article-title":"Effects of using free sample medications on the prescribing practices of family physicians","volume":"19","author":"Symm","year":"2006","journal-title":"Journal of the American Board of Family Medicine: JABFM"},{"issue":"4","key":"10.1002\/14651858.CD013423.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/MLR.0000000000000329","article-title":"Antipsychotic prescribing: do conflict of interest policies make a difference?","volume":"53","author":"Anderson","year":"2015","journal-title":"Medical Care"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1377\/hlthaff.2019.01289","article-title":"The impact of academic medical center policies restricting direct-to-physician marketing on opioid prescribing","volume":"39","author":"Eisenberg","year":"2020","journal-title":"Health Affairs (Project Hope)"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1370\/afm.1135","article-title":"Effect of drug sample removal on prescribing in a family practice clinic","volume":"8","author":"Hartung","year":"2010","journal-title":"Annals of Family Medicine"},{"issue":"17","key":"10.1002\/14651858.CD013423.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2017.4039","article-title":"Association between academic medical center pharmaceutical detailing policies and physician prescribing","volume":"317","author":"Larkin","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MLR.0b013e318277eb19","article-title":"Does exposure to conflict of interest policies in psychiatry residency affect antidepressant prescribing?","volume":"51","author":"Epstein","year":"2013","journal-title":"Medical Care"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/qhc.12.1.29","article-title":"Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey","volume":"12","author":"Watkins","year":"2003","journal-title":"Quality & Safety in Health Care"},{"issue":"10","key":"10.1002\/14651858.CD013423.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jamainternmed.2019.0999","article-title":"Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians","volume":"179","author":"Khan","year":"2019","journal-title":"JAMA Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD013423.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jamainternmed.2016.1709","article-title":"Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts","volume":"176","author":"Yeh","year":"2016","journal-title":"JAMA Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013423.pub3-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s11606-021-06980-6","article-title":"Associations between industry payments to physicians for antiplatelet drugs and utilization of cardiac procedures and stents","volume":"37","author":"Yanagisawa","year":"2022","journal-title":"Journal of General Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013423.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/0194599819852321","article-title":"The association between industry payments and brand-name prescriptions in otolaryngologists","volume":"161","author":"Morse","year":"2019","journal-title":"Otolaryngology \u2013 Head and Neck Surgery"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"e0155474","DOI":"10.1371\/journal.pone.0155474","article-title":"Physician payments from industry are associated with greater Medicare Part D prescribing costs","volume":"11","author":"Perlis","year":"2016","journal-title":"PLOS One"},{"issue":"10","key":"10.1002\/14651858.CD013423.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1425\u201328","DOI":"10.1001\/jamainternmed.2019.1082","article-title":"Association between industry payments to physicians and gabapentinoid prescribing","volume":"179","author":"Rhee","year":"2019","journal-title":"JAMA Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/hec.3993","article-title":"The impact of reducing pharmaceutical industry payments on physician prescribing","volume":"29","author":"Parker-Lue","year":"2020","journal-title":"Health Economics"},{"issue":"13","key":"10.1002\/14651858.CD013423.pub3-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1007\/s11606-022-07457-w","article-title":"Effects and trends in opioid-related promotional payments between 2014 and 2019: a panel data analysis among prescribers in Medicare Part D","volume":"37","author":"Pope","year":"2022","journal-title":"Journal of General Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013423.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/pds.4224","article-title":"Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing","volume":"26","author":"Qian","year":"2017","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"9","key":"10.1002\/14651858.CD013423.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/SMJ.0b013e3181814d52","article-title":"The impact of drug samples on prescribing to the uninsured","volume":"101","author":"Miller","year":"2008","journal-title":"Southern Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jamadermatol.2013.9715","article-title":"Characterizing the relationship between free drug samples and prescription patterns for acne vulgaris and rosacea","volume":"150","author":"Hurley","year":"2014","journal-title":"JAMA Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A clinical overview of off-label use of gabapentinoid drugs","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Internal Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12940-016-0156-6","article-title":"A proposed framework for the systematic review and integrated assessment (SYRINA) of endocrine disrupting chemicals","volume":"15","author":"Vandenberg","year":"2016","journal-title":"Environmental Health"},{"issue":"5","key":"10.1002\/14651858.CD013423.pub3-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1377\/hlthaff.2010.1219","article-title":"An evidence-based medicine methodology to bridge the gap between clinical and environmental health sciences","volume":"30","author":"Woodruff","year":"2011","journal-title":"Health Affairs"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/0141076814562718","article-title":"The environment and disease: association or causation?","volume":"108","author":"Hill","year":"2015","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013423.pub3-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"336\u201351","DOI":"10.1002\/jrsm.1310","article-title":"Dealing with effect size multiplicity in systematic reviews and meta-analyses","volume":"9","author":"L\u00f3pez-L\u00f3pez","year":"2018","journal-title":"Research Synthesis Methods"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08911762.2021.1949084","article-title":"Ethical issues in pharmaceutical marketing: a systematic review and future research agenda","volume":"35","author":"Limbu","year":"2022","journal-title":"Journal of Global Marketing"},{"issue":"8","key":"10.1002\/14651858.CD013423.pub3-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"e0306886","DOI":"10.1371\/journal.pone.0306886","article-title":"Assessing the impact of the Physician Payments Sunshine Act on pharmaceutical companies\u2019 payments to physicians","volume":"19","author":"Cheng","year":"2024","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0176|cit176","unstructured":"Zheng M Health professionals' risk of conflict of interest even from routine meals sponsored by drug firms: expert; 22 March 2022 Epoch Times. Available at: https:\/\/www.theepochtimes.com\/world\/frequent-interactions-between-clinicans-and-big-pharma-a-conflict-of-interest-expert-4353144"},{"issue":"4","key":"10.1002\/14651858.CD013423.pub3-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"511","DOI":"10.18433\/j3kk6c","article-title":"Effectiveness of academic detailing to optimize medication prescribing behaviour of family physicians","volume":"16","author":"Chhina","year":"2013","journal-title":"Journal of Pharmacy & Pharmaceutical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD013423.pub3-BIB0178|cit178","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000409.pub2","article-title":"Educational outreach visits: effects on professional practice and health care outcomes","author":"O\u2019Brien","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013423.pub3-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s11606-021-06799-1","article-title":"Learning from the opioid epidemic: preventing the next healthcare marketing crisis","volume":"36","author":"Uppal","year":"2021","journal-title":"Journal of General Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013423.pub3-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"e186007","DOI":"10.1001\/jamanetworkopen.2018.6007","article-title":"Association of pharmaceutical industry marketing of opioid products with mortality from opioid-related overdoses","volume":"2","author":"Hadland","year":"2019","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1002\/14651858.CD013423.pub3-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11606-018-4700-7","article-title":"Concentration of opioid-related industry payments in opioid crisis areas","volume":"34","author":"Lee","year":"2019","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0182|cit182","unstructured":"Sanborn BJ Pharma reps not welcome? More hospitals, practices granting \u2018no access\u2019 to salespeople; 1 November 2017 Healthcare Finance. Available at https:\/\/www.healthcarefinancenews.com\/news\/pharma-reps-not-welcome-more-hospitals-practices-granting-no-access-salespeople"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0183|cit183","unstructured":"Taylor NP The doctor won\u2019t see you now: survey shows pullback from in-person rep meetings, rise of omnichannel; 29 March 2023 Fierce Pharma. Available at: https:\/\/www.fiercepharma.com\/marketing\/doctor-wont-see-you-now-survey-shows-pullback-person-rep-meetings-rise-omnichannel"},{"key":"10.1002\/14651858.CD013423.pub3-BIB0184|cit184","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:47:48Z","timestamp":1793274468000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013423.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":184,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013423.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]}}}